Richard Nolan Townsend - 12 Sep 2025 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role: Chief Executive Officer, Director
Signature: /s/ Youjin Choi, Attorney-in-Fact
Issuer symbol: LXEO
Transactions as of: 12 Sep 2025
Net transactions value: +$5,798
Form type: 4
Filing time: 16 Sep 2025, 17:30:06 UTC
Previous filing: 10 Sep 2025
Next filing: 17 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Townsend Richard Nolan	Chief Executive Officer, Director	C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK	/s/ Youjin Choi, Attorney-in-Fact	16 Sep 2025	0001995218

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LXEO	Common Stock	Award	$5,798	+2,193	+1%	$2.64	222,251	12 Sep 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
F2	Includes 131,092 Restricted Stock Units.